Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib + EGFR-TKI in EGFR-TKI-resistant NSCLC
NCT03050411Phase 1Unknown
- Sponsor
- Peking University Third Hospital
- Start
- May 2016
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Rivoceranib in non-small cell lung cancer (NSCLC), sponsored by Peking University Third Hospital. Primary endpoint: Optimal Dosage at 9 months. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03050411.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03050411.